ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
신경피부질환 시장 규모는 최근 수년간 강력하게 성장하고 있습니다. 2024년 20억 5,000만 달러에서 2025년에는 22억 2,000만 달러에 달하고, CAGR 8.5%로 성장할 전망입니다. 지난 수년간의 성장 원동력은 유전성 질환의 유병률 증가, 희귀 신경 질환에 대한 인식 증가, 영상 진단 채택 확대, 전문 클리닉에 대한 환자 방문 증가, 소아 신경학에 대한 임상적 관심 증가였습니다.
신경피부질환 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 8.2%로 30억 4,000만 달러로 성장할 전망입니다. 예측기간 내 성장은 표적약 치료에 대한 수요 증가, 희소질환의 임상시험 활동 확대, 연구기관 간 협력관계 증가, 유전자검사서비스의 폭넓은 채용, 신경의료에 대한 의료비 증가 등에 의해 지원될 것으로 예측됩니다. 예측 기간 동안 예상되는 주요 동향으로는 유전체 시퀀싱의 진보, 유전자 치료 응용의 혁신, 신규 치료법의 연구 개발 투자 증가, 디지털 건강 모니터링 도구의 발전, 바이오마커 기반 진단의 진보 등이 있습니다.
유전성 질환의 유병률 증가는 신경피부질환 시장의 확대를 지원할 것으로 예측됩니다. 유전성 질환이란 개인의 DNA의 변화나 이상에 의해 야기되는 병상을 말하며, 유전되는 경우도 있으며 자연적으로 발병하는 경우도 있습니다. 결절 경화증 및 신경 섬유종증과 같은 신경 피부 질환은 신경계와 피부 모두에 영향을 미치는 특정 유전자 변이에 의해 유발되어 신경 증상과 명확한 피부 증상이 결합합니다. 유전자 검사의 진보나 인지도의 향상이 조기 진단에 공헌하고 있어 보고되고 있는 유병률이 높아지고 있습니다. 예를 들어, 2024년 11월 미국에 본부를 두고 있는 정부기관인 질병대책예방센터는 미국에서 신생아의 약 33명 중 1명이 선천성 장애를 가지고 태어났으며, 그 대부분은 유전적 원인과 관련되어 있다고 보고하고 있습니다. 따라서 유전성 질환의 발생률이 증가하면서 신경피부질환 시장의 성장이 지속되고 있습니다.
신경피부질환 시장의 주요 기업들은 치료의 폭을 넓히고, 환자의 예후를 개선하며, 혁신적인 치료에 대한 수요 증가에 대응하기 위해 규제 당국의 승인을 우선하고 있습니다. 약사 승인은 의약품의 안전성과 효능을 확인한 후 시험, 마케팅 및 판매를 허용하는 정부 당국의 정식 허가를 의미합니다. 예를 들어, 영국에 본사를 두는 제약 및 생명공학 기업인 아스트라제네카는 2025년 9월, 'Koselugo'로 시판되고 있는 셀루메티닙을 수술이 불가능한 총상 신경 섬유종을 나타내는 1세 이상의 증후성 신경 섬유종증 1형의 소아 환자에게 사용하는 것에 대해 승인을 받았습니다. 이 승인은 2세 이상의 어린이를 대상으로 하는 기존의 적응을 확대하는 것입니다. 셀루메티닙은 MEK 억제제이며 신경 섬유종증 1형의 종양 발생에 관여하는 MAPK 경로를 표적으로 합니다. 치료는 1일 2회 경구 투여되고, 병세 진행 또는 견딜 수 없는 부작용이 발현될 때까지 계속됩니다. 일반적인 부작용으로는 위장 장애, 피부 반응, 심장 합병증, 시력 관련 문제 등이 있습니다. 이번 승인은 복잡하고 종종 외관을 손상시키거나 외과적 절제가 어려운 종양을 앓고 있는 유아에게 중요한 치료 옵션을 제공합니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 신경피부질환 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 신경피부질환 시장 : 성장률 분석
세계의 신경피부질환 시장 실적 : 규모와 성장(2019-2024년)
세계의 신경피부질환 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 신경피부질환 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 신경피부질환 시장 : 신경피부질환 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
신경섬유종증
결절성 경화증
스터지 웨버 증후군
혈관종증
이토 색소실조증
세계의 신경피부질환 시장 : 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
약물 치료
외과적 개입
레이저 요법
물리치료
심리사회적 지원
세계의 신경피부질환 시장 : 연령층별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
소아 환자(0-18세)
성인 환자(19-65세)
고령 환자(65세 이상)
세계의 신경피부질환 시장 : 중증도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
경증
경중증
중증
위급
세계의 신경피부질환 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
가정 간병 환경
연구기관
제약기업
세계의 신경피부질환 시장 세분화 : 신경섬유종증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
말초신경 섬유종증
중추신경 섬유종증
총상신경 섬유종증
세계의 신경피부질환 시장 세분화 : 결절성 경화증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
고전적 결절성 경화증
유아기 발병 결절성 경화증
성인 발병 결절성 경화증
세계의 신경피부질환 시장 세분화 : 스터지 웨버 증후군 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
안면 스터지 웨버 증후군
뇌성 스터지 웨버 증후군
안구 스터지 웨버 증후군
세계의 신경피부질환 시장 세분화 : 혈관종증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
범발성 혈관종증
국소 혈관종증
혼합성 혈관종증
세계의 신경피부질환 시장 세분화 : 이토 색소실조증 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
선형 색소실조증
분절성 색소실조증
와류상 색소실조증
제7장 지역별/국가별 분석
세계의 신경피부질환 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 신경피부질환 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
신경피부질환 시장 : 경쟁 구도
신경피부질환 시장 : 기업 프로파일
Merck KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Recursion Pharmaceuticals Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Takeda Pharmaceutical Company Limited
Labcorp Holdings Inc.
Quest Diagnostics Incorporated
Eurofins Scientific SE
Fosun Pharmaceutical Group Co. Ltd.
ioMarin Pharmaceutical Inc.
Simcere Pharmaceutical Group
Marinus Pharmaceuticals Inc.
Inhibikase Therapeutics Inc.
Healx Limited
NF2 Therapeutics Inc.
NFlection Therapeutics Inc.
Ovid Therapeutics Inc.
CureAge Therapeutics
GW Pharmaceuticals plc
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
신경피부질환 시장(2029년) : 새로운 기회를 제공하는 국가
신경피부질환 시장(2029년) : 새로운 기회를 제공하는 부문
신경피부질환 시장(2029년) : 성장전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
A neurocutaneous disorder is a group of genetic conditions that affect both the nervous system and the skin, often present from birth due to mutations that disrupt normal cell growth and development. These disorders typically manifest with visible skin abnormalities such as birthmarks, lesions, or tumors, along with neurological complications including seizures, developmental delays, or cognitive impairments.
The primary types of neurocutaneous disorders include neurofibromatosis, tuberous sclerosis complex, Sturge-Weber syndrome, angiomatosis, and hypomelanosis of Ito. Neurofibromatosis encompasses NF1, NF2, and schwannomatosis, genetic conditions that cause tumor growth along nerves. Treatments include pharmacological therapy, surgical intervention, laser therapy, and physical or psychosocial support. These disorders affect various age groups, including pediatric patients (0-18 years), adults (19-65 years), and geriatric patients (65 years and above), and range in severity from mild to critical cases. Key end-users include hospitals, specialist clinics, homecare settings, research organizations, and pharmaceutical companies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The neurocutaneous disorder market research report is one of a series of new reports from The Business Research Company that provides neurocutaneous disorder market statistics, including neurocutaneous disorder industry global market size, regional shares, competitors with a neurocutaneous disorder market share, detailed neurocutaneous disorder market segments, market trends and opportunities, and any further data you may need to thrive in the neurocutaneous disorder industry. This neurocutaneous disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The neurocutaneous disorder market size has grown strongly in recent years. It will grow from $2.05 billion in 2024 to $2.22 billion in 2025 at a compound annual growth rate (CAGR) of 8.5%. Growth in the historic period was driven by the rising prevalence of genetic disorders, increasing awareness of rare neurological conditions, greater adoption of diagnostic imaging, higher patient visits to specialty clinics, and growing clinical focus on pediatric neurology.
The neurocutaneous disorder market size is expected to see strong growth in the next few years. It will grow to $3.04 billion in 2029 at a compound annual growth rate (CAGR) of 8.2%. Growth in the forecast period is expected to be supported by increasing demand for targeted drug therapies, expansion of clinical trial activities for rare diseases, rising collaborations among research institutes, wider adoption of genetic testing services, and higher healthcare expenditure on neurological care. Key trends anticipated for the forecast period include advancements in genomic sequencing, innovation in gene therapy applications, increased investment in research and development for novel treatments, developments in digital health monitoring tools, and progress in biomarker-based diagnostics.
The growing prevalence of genetic disorders is anticipated to support the expansion of the neurocutaneous disorder market. Genetic disorders are medical conditions caused by changes or abnormalities in an individual's DNA, which may be inherited or occur spontaneously. Neurocutaneous disorders, including conditions such as tuberous sclerosis complex and neurofibromatosis, are caused by specific genetic mutations that affect both the nervous system and the skin, resulting in a combination of neurological symptoms and distinct dermatological signs. Advances in genetic testing and increased awareness are contributing to earlier diagnosis, which has led to a higher reported prevalence. For example, in November 2024, the Centers for Disease Control and Prevention, a government agency based in the United States, reported that approximately one in every thirty-three newborns in the country is born with a birth defect, many of which are linked to genetic causes. Therefore, the increasing incidence of genetic disorders is driving the growth of the neurocutaneous disorder market.
Leading companies within the neurocutaneous disorder market are prioritizing regulatory approvals to broaden their treatment offerings, improve patient outcomes, and meet growing demand for innovative therapies. Regulatory approvals refer to formal authorization from government authorities that permit the testing, marketing, or sale of a pharmaceutical product after confirming its safety and efficacy. For instance, in September 2025, AstraZeneca, a pharmaceutical and biotechnology company based in the United Kingdom, received approval from the Food and Drug Administration to market selumetinib, known commercially as Koselugo, for use in pediatric patients aged one year and older with neurofibromatosis type one who present with symptomatic and inoperable plexiform neurofibromas. This approval extends the previous indication, which covered children aged two years and older. Selumetinib is a MEK inhibitor that works by targeting the MAPK pathway, which plays a role in tumor development in neurofibromatosis type one. The treatment is administered orally twice daily and continued until disease progression or intolerable side effects arise. Common side effects include gastrointestinal issues, skin reactions, cardiac complications, and vision-related problems. This regulatory approval provides a vital treatment option for younger children affected by these complex and often disfiguring tumors, which are typically challenging to remove surgically.
In October 2022, Pasithea Therapeutics Corporation, a biotechnology company based in the United States, acquired AlloMek Therapeutics for an undisclosed amount. Through this acquisition, Pasithea seeks to expand its drug development pipeline focused on central nervous system disorders, with a particular emphasis on rare genetic conditions known as RASopathies. The deal is expected to support long-term growth and create potential synergies with Pasithea's ongoing research in multiple sclerosis. AlloMek Therapeutics is a pharmaceutical company based in the United States that developed CIP-137401, a macrocyclic MEK inhibitor aimed at treating neurocutaneous disorders.
Major players in the neurocutaneous disorder market are Merck KGaA, AbbVie Inc., Sanofi S.A., Novartis AG, Recursion Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Labcorp Holdings Inc., Quest Diagnostics Incorporated, Eurofins Scientific SE, Fosun Pharmaceutical Group Co. Ltd., ioMarin Pharmaceutical Inc., Simcere Pharmaceutical Group, Marinus Pharmaceuticals Inc., Inhibikase Therapeutics Inc., Healx Limited, NF2 Therapeutics Inc., NFlection Therapeutics Inc., Ovid Therapeutics Inc., CureAge Therapeutics, GW Pharmaceuticals plc.
North America was the largest region in the neurocutaneous disorder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurocutaneous disorder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the neurocutaneous disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The neurocutaneous disorder market includes revenues earned by entities by providing services, such as pharmacological treatment, medical consultation and diagnosis, psychological and behavioral support, and clinical trials and research participation. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Neurocutaneous Disorder Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on neurocutaneous disorder market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for neurocutaneous disorder ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neurocutaneous disorder market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type Of Neurocutaneous Disorder: Neurofibromatosis; Tuberous Sclerosis Complex; Sturge-Weber Syndrome; Angiomatosis; Hypomelanosis Of Ito
2) By Treatment Type: Pharmacological Treatment; Surgical Intervention; Laser Therapy; Physical Therapy; Psychosocial Support
3) By Age Group: Pediatric Patients (0-18 Years); Adult Patients (19-65 Years); Geriatric Patients (65 Years And Above)
4) By Severity Of Condition: Mild Cases; Moderate Cases; Severe Cases; Critical Cases
5) By End User: Hospitals; Specialist Clinics; Homecare Settings; Research Organizations; Pharmaceutical Companies
Subsegments:
1) By Neurofibromatosis: Peripheral Neurofibromatosis; Central Neurofibromatosis; Plexiform Neurofibromatosis
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Neurocutaneous Disorder Market Characteristics
3. Neurocutaneous Disorder Market Trends And Strategies
4. Neurocutaneous Disorder Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Neurocutaneous Disorder Growth Analysis And Strategic Analysis Framework
5.1. Global Neurocutaneous Disorder PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Neurocutaneous Disorder Market Growth Rate Analysis
5.4. Global Neurocutaneous Disorder Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Neurocutaneous Disorder Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Neurocutaneous Disorder Total Addressable Market (TAM)
6. Neurocutaneous Disorder Market Segmentation
6.1. Global Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neurofibromatosis
Tuberous Sclerosis Complex
Sturge-Weber Syndrome
Angiomatosis
Hypomelanosis Of Ito
6.2. Global Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmacological Treatment
Surgical Intervention
Laser Therapy
Physical Therapy
Psychosocial Support
6.3. Global Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric Patients (0-18 Years)
Adult Patients (19-65 Years)
Geriatric Patients (65 Years And Above)
6.4. Global Neurocutaneous Disorder Market, Segmentation By Severity Of Condition, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mild Cases
Moderate Cases
Severe Cases
Critical Cases
6.5. Global Neurocutaneous Disorder Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialist Clinics
Homecare Settings
Research Organizations
Pharmaceutical Companies
6.6. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Neurofibromatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Peripheral Neurofibromatosis
Central Neurofibromatosis
Plexiform Neurofibromatosis
6.7. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Tuberous Sclerosis Complex, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Classic Tuberous Sclerosis
Infantile-Onset Tuberous Sclerosis
Adult-Onset Tuberous Sclerosis
6.8. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Sturge-Weber Syndrome, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Facial Sturge-Weber Syndrome
Cerebral Sturge-Weber Syndrome
Ophthalmic Sturge-Weber Syndrome
6.9. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Angiomatosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Generalized Angiomatosis
Localized Angiomatosis
Mixed Angiomatosis
6.10. Global Neurocutaneous Disorder Market, Sub-Segmentation Of Hypomelanosis Of Ito, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Linear Hypomelanosis
Segmental Hypomelanosis
Whorled Hypomelanosis
7. Neurocutaneous Disorder Market Regional And Country Analysis
7.1. Global Neurocutaneous Disorder Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Neurocutaneous Disorder Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Neurocutaneous Disorder Market
9.1. China Neurocutaneous Disorder Market Overview
9.2. China Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Neurocutaneous Disorder Market
10.1. India Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Neurocutaneous Disorder Market
11.1. Japan Neurocutaneous Disorder Market Overview
11.2. Japan Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Neurocutaneous Disorder Market
12.1. Australia Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Neurocutaneous Disorder Market
13.1. Indonesia Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Neurocutaneous Disorder Market
14.1. South Korea Neurocutaneous Disorder Market Overview
14.2. South Korea Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Neurocutaneous Disorder Market
15.1. Western Europe Neurocutaneous Disorder Market Overview
15.2. Western Europe Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Neurocutaneous Disorder Market
16.1. UK Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Neurocutaneous Disorder Market
17.1. Germany Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Neurocutaneous Disorder Market
18.1. France Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Neurocutaneous Disorder Market
19.1. Italy Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Neurocutaneous Disorder Market
20.1. Spain Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Neurocutaneous Disorder Market
21.1. Eastern Europe Neurocutaneous Disorder Market Overview
21.2. Eastern Europe Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Neurocutaneous Disorder Market
22.1. Russia Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Neurocutaneous Disorder Market
23.1. North America Neurocutaneous Disorder Market Overview
23.2. North America Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Neurocutaneous Disorder Market
24.1. USA Neurocutaneous Disorder Market Overview
24.2. USA Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.2. Canada Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Neurocutaneous Disorder Market
26.1. South America Neurocutaneous Disorder Market Overview
26.2. South America Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Neurocutaneous Disorder Market
27.1. Brazil Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Neurocutaneous Disorder Market
28.1. Middle East Neurocutaneous Disorder Market Overview
28.2. Middle East Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Neurocutaneous Disorder Market
29.1. Africa Neurocutaneous Disorder Market Overview
29.2. Africa Neurocutaneous Disorder Market, Segmentation By Type Of Neurocutaneous Disorder, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Neurocutaneous Disorder Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Neurocutaneous Disorder Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Neurocutaneous Disorder Market Competitive Landscape And Company Profiles
